Original Research Article

Histopathological study of epithelial ovarian tumors with special reference to human epidermal growth factor receptor-2/NEU and CA-125 expression

Shobnam Bahar Barbhuiya, Ananya Debnath*, Monoj Kumar Deka, Shah Alam Sheikh

Department of Pathology, Silchar Medical College and Hospital, Silchar, Assam, India

Received: 14 March 2021
Revised: 17 April 2021
Accepted: 19 April 2021

*Correspondence:
Dr. Ananya Debnath,
E-mail: tiadebnath21@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Ovarian cancer is the second most common gynecologic malignancy. The aim of the study was to evaluate the tissue expression of HER-2/NEU and CA-125 in various epithelial ovarian carcinoma and assess the prognostic significance.

Methods: A retrospective study was done in 76 cases of ovarian tumor. IHC was done in 16 cases of epithelial ovarian cancer with HER-2/NEU and CA-125.

Results: Total number of cases were 76. Out of these 76 cases, 22 cases were malignant. 16 cases were malignant epithelial ovarian cancer. The highest incidence of malignant tumor was seen in the 41-50 years age group with 9 cases (11.84%). Out of 11 serous adenocarcinoma, 9 cases (81.8%) showed tissue expression of CA-125 and rest 2 cases (18.18%) did not show expression. All the 5 cases (100%) of mucinous adenocarcinoma did not show any tissue expression of CA-125. HER-2/NEU expression was positive in 7 out of 16 cases that is 43.75% and negative expression was seen in 9 out of 16 cases that is 56.25% of cases. Maximum HER-2/NEU positivity is seen among grade 3 tumors, that is (62.5%) (5 out of 8 cases).

Conclusions: The incidence of epithelial ovarian tumors are more common. The tissue expression of CA-125 on malignant epithelial ovarian tumors was studied, which showed positive expression in serous cystadenocarcinomas, but not in mucinous cystadenocarcinoma. HER-2/NEU expression was seen to be increasing with advanced grade of the tumors.

Keywords: Epithelial ovarian cancer, HER-2/NEU, CA-125

INTRODUCTION

Ovarian cancer is the second most common gynecologic malignancy and the major cause of gynecologic cancer death.1 In most of the population based cancer registries across India, ovary is the third leading site of cancer among women, trailing behind cervix and breast.2 According to WHO histological classification based on the most probable tissue of origin, ovarian tumors are broadly classified under- (a) surface epithelial-stromal tumors; (b) sex cord-stromal tumors; (c) germ cell tumors; and (d) metastatic cancer from non-ovarian primary.3 Epithelial ovarian cancer accounts for about 80-90% of all ovarian malignancy and about 60% of all ovarian tumors. Traditionally the five main subtypes of epithelial ovarian cancer are serous, mucinous, endometrioid, clear cell and transitional cell (Brenner type) tumors.4 HER-2 (human epidermal growth factor receptor-2) protooncogene encodes a transmembrane glycoprotein belonging to EGFR tyrosine kinase receptor family. Over-expression of HER-2 initiates intracellular signalling pathways involved in cell proliferation, differentiation, migration and apoptosis.5
CA-125 (MUC 16) is a high molecular weight, membrane associated mucin, which is aberrantly expressed in advanced serous epithelial ovarian carcinoma. CA-125 is the gold standard tumor marker in ovarian cancer. Serum level of CA-125 is used to monitor response to chemotherapy, relapse and disease progression in ovarian cancer patients.

The aim of the study was to evaluate the tissue expression of HER-2/NEU and CA-125 in various epithelial ovarian carcinoma and assess the prognostic significance.

**METHODS**

The study was done for a period of one year from December 2018 to November 2019. This was a retrospective study done in the department of pathology, Silchar Medical College and Hospital. Ethical approval was taken from the ethical committee of Silchar Medical College and Hospital and it was approved in terms of scientific researches and patient ethics. 76 cases of ovarian tumor specimens were included in the study.

**Inclusion criteria**

All patients irrespective of age with ovarian masses were included in the study.

**Exclusion criteria**

Non-neoplastic mass was excluded from the study.

Samples were collected using stratified random sampling technique. All the data were analyzed using Microsoft excel 2013 and figures were inserted using Microsoft word 2013.

After fixation with 10% neutral buffered formaldehyde, the specimen was grossed using standard protocol. The sections were paraffin embedded and stained with hematoxylin and eosin (H and E). IHC study was done in malignant tumors of epithelial origin. Appropriate sections were prepared on poly-L-lysine coated slides for IHC using CA-125 and HER-2/NEU following standard protocol. The CA-125 stains the cell membrane. A positive HER-2/NEU IHC reaction was considered in the presence of brown membrane staining.

**RESULTS**

In this study, a total number of 76 ovarian tumor specimens were obtained, out of which 52 (68.42%) were benign, 2 (2.63%) were borderline and 22 (28.94%) were malignant (Table 1).

The tumors were categorized according to different age groups as shown in Table-2. The highest incidence of malignant tumors was seen in the 41-50 years age group with 9 cases (11.84%) (Table 2).

In this study, 45 cases (59.21%) were epithelial tumors, 25 cases (32.89%) were germ cell tumor, 5 cases (6.57%) were sex cord stromal tumors and 1 case (1.31%) was metastatic tumor. In this study, among the benign tumors, mature cystic teratoma was the commonest, accounting for 22 cases (28.94%) followed by serous cystadenoma, accounting for 18 cases (23.68%) and mucinous cystadenoma, accounting for 8 cases (10.52%). In the malignant group, serous cystadenocarcinoma accounted for 11 cases (14.47%) of which the papillary variety was the commonest (Table 3). In the benign epithelial tumor group, serous cystadenoma accounted for 18 cases (23.68%) was the commonest. In the malignant group, papillary serous adenocarcinoma was the commonest, 7 cases (9.21%).

**Table 1: Number of cases.**

| Groups       | No. of cases | Percentage (%) |
|--------------|--------------|----------------|
| Benign       | 52           | 68.42          |
| Borderline   | 2            | 2.63           |
| Malignant    | 22           | 28.94          |

**Table 2: Age group.**

| Age group (years) | Benign | Borderline | Malignant |
|-------------------|--------|------------|-----------|
| 0-10              | 0      | 0          | 1         |
| 11-20             | 6      | 0          | 0         |
| 21-30             | 14     | 0          | 1         |
| 31-40             | 20     | 0          | 4         |
| 41-50             | 10     | 2          | 9         |
| 51-60             | 2      | 0          | 7         |

**Table 3: Frequency of different histological types of ovarian tumors.**

| Histological types | No. of cases | Percentage (%) |
|--------------------|--------------|----------------|
| Benign             |              |                |
| Serous cystadenoma | 18           | 23.68          |
| Mucinous cystadenoma | 8          | 10.52          |
| Mature cystic teratoma | 22         | 28.94          |
| Fibroma            | 3            | 3.94           |
| Benign brenner     | 1            | 1.31           |
| Borderline         |              |                |
| Brenner borderline | 1            | 1.31           |
| Serous borderline  | 1            | 1.31           |
| Malignant          |              |                |
| Papillary serous adenocarcinoma | 7 | 9.21 |
| Serous cystadenocarcinoma | 4 | 5.26 |
| Mucinous cystadenocarcinoma | 5 | 6.57 |
| Granulosa cell tumor | 2 | 2.63 |
| Dysgerminoma       | 1            | 1.31           |
| Yolk sac tumor     | 2            | 2.63           |
| Metastatic tumor (Krukenberg tumor) | 1 | 1.31 |
There were total 16 malignant surface epithelial ovarian tumors, 11 serous adenocarcinoma and 5 mucinous adenocarcinoma. Out of 11 serous adenocarcinoma, 9 cases (81.8%) showed tissue expression of CA-125 and rest 2 cases (18.18%) did not show expression. All the 5 cases (100%) of mucinous adenocarcinoma did not show any tissue expression of CA-125 (Table 4).

| Type of tumor               | No. of cases | CA-125 (+) | CA-125 (-) |
|-----------------------------|--------------|------------|------------|
| Serous adenocarcinoma       | 11           | 9          | 2          |
| Mucinous adenocarcinoma     | 5            | 0          | 5          |
| Total                       | 16           | 9          | 7          |

Expression of HER-2/NEU with histopathologic type and grade was studied. HER-2/NEU expression was positive in 7 out of 16 cases that is 43.75% and negative expression was seen in 9 out of 16 cases that is 56.25% of cases (Table 5-6).

| HER-2/NEU status | No. of cases | Percentage (%) |
|------------------|--------------|----------------|
| Negative         | 9            | 56.25          |
| Positive         | 7            | 43.75          |
| Total            | 16           | 100            |

Table 6: Histological type.

| Histological type        | HER-2/NEU (+) | HER-2/NEU (-) |
|--------------------------|---------------|---------------|
| Serous adenocarcinoma    | 5             | 6             |
| Mucinous adenocarcinoma  | 2             | 3             |

From Table 7, it is seen that out of 16 cases, 3 cases (18.75%) were grade 1, 5 cases (31.25%) were grade 2 and 8 cases (50%) were grade 3. Maximum HER-2/NEU positivity is seen among grade 3 tumors, that is 62.5% (5 out of 8 cases) (Table 7). HER-2/NEU expression was found to be increasing with increase of grade.

**Table 7: Distribution of tumors according to Universal grading system of ovarian cancer was done.**

| Grade | No. of cases | Percentage (%) | Negative | Positive |
|-------|--------------|----------------|----------|----------|
| 1     | 3            | 18.75          | 2        | 1        |
| 2     | 5            | 31.25          | 4        | 1        |
| 3     | 8            | 50             | 3        | 5        |
| Total | 16           | 100            | 9        | 7        |

DISCUSSION

The study was carried out in total of 76 patients admitted in Silchar Medical College and Hospital, Silchar who underwent suspected ovarian tumor removal during the period of December 2018 to November 2019. Out of the 76 ovarian tumors, 52 (68.42%) were benign, 22 (28.94%) were malignant and 2 (2.63%) were borderline. Francisco et al (1993) reported 80.7% benign, 16.9% malignant and 2.3% borderline. Rajan (1994) reported 94% tumors as benign and rest as malignant including tumors of borderline malignancy.
The highest incidence of malignant tumor was seen in the 41-50 years age group with 9 cases (11.84%). Gupta et al (1986), Prabhakar et al (1989) and Sarkar (1996) reported the maximum incidence were in third and fourth decades of life which tallies with the observation of our study.\textsuperscript{10}

All these 76 tumors were examined histologically and classified into the following broad groups: common epithelial tumor (59.21%), germ cell (32.89%), sex cord (6.57%) and metastatic (1.31%). Claude Gompel and Silverberg (1985) held that epithelial tumor of ovary to be 60% and while Sarkar (1996) reported 66.8%.\textsuperscript{11,10}

In the present study, an attempt was made to evaluate the immunohistochemical role of CA-125 in detecting malignant epithelial ovarian tumor. 16 cases of malignant epithelial ovarian tumor had 11 serous adenocarcinoma and 5 mucinous adenocarcinoma. Fukazawa et al in their study found that CA-125 was not expressed in ovarian mucinous cystadenocarcinoma but was demonstrated immunohistochemically in 82% of ovarian serous cystadenocarcinomas.\textsuperscript{12} Similarly, Neunteufel et al had all mucinous tumors to be CA-125 negative.\textsuperscript{13} So, in our study, out of total 11 serous adenocarcinoma, CA-125 was expressed in 9 cases (81.8%) and no expression in mucinous adenocarcinoma.

In our study, HER-2/NEU positive expression was found in 7 out of 16 cases (43.75%) and negative in 9 out of 16 cases (56.25%). Ajani et al study reported 41.3% serous carcinoma were HER-2/NEU positive.\textsuperscript{14} Marinas et al had 55.5% HER-2/NEU serous adenocarcinoma positive.\textsuperscript{15} In our study, this was 45.45%.

Goel et al had HER-2/NEU positivity of mucinous adenocarcinoma in 66.7%.\textsuperscript{7} While Vrabie et al had HER-2/NEU positivity of mucinous adenocarcinoma in 41.66% of cases.\textsuperscript{16} In our study this was 40%.

Studies by Ajani et al and Mahdi et al showed HER-2/NEU positivity increased with higher grades of ovarian epithelial carcinoma.\textsuperscript{14,17} The above studies are in concordance with the findings of present study.

\textbf{Limitations}

This study had some limitations as the study period was only for one-year duration, long term follow-up of patients was not possible and thus the prognosis of most patients were not known.

\textbf{CONCLUSION}

A tentative conclusion can be drawn from the present study that benign ovarian tumors are more common than the malignant counterpart. Moreover, the incidence of epithelial tumors are more common. The tissue expression of CA-125 on malignant epithelial ovarian tumors was studied, which showed positive expression in serous cystadenocarcinomas, but not in mucinous cystadenocarcinoma.

HER-2/NEU expression was seen to be increasing with advanced grade of the tumors.

As the study period was only for one-year duration, long term follow-up of patients were not possible and thus the prognosis of most patients were not known. However, long term follow-up of these patients are needed with proper management and early detection of recurrences especially by the use of CA-125 in cases of malignant tumors of epithelial origin.

\textbf{Funding: No funding sources}

\textbf{Conflict of interest: None declared}

\textbf{Ethical approval: The study was approved by the Institutional Ethics Committee}

\textbf{REFERENCES}

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.

2. Basu P, De P, Mandal S, Ray K, Biswas J. Study of ‘patterns of care’ of ovarian cancer patients in a specialized cancer institute in Kolkata, eastern India. Indian J Cancer. 2009;46(1):28-33.

3. Ellenson LH, Pirog EC. The female genital tract. In: Kumar V, Abbas AK, Aster JC, eds. Robbins and Cotran pathologic basis of disease. 9th ed. Philadelphia: Elsevier Saunders; 2015: 1022-1023.

4. Sarkar M, Jha T, Das TK, Sau V, Mitra S, Roy K. Spectrum of epithelial ovarian tumors with HER2/NEU expression by the carcinomas among patients admitted in a tertiary care hospital in Eastern India. Int J Med Sci Public Health. 2015;4(10):1388-92.

5. Goel S, Mehra M, Yadav A, Sharma M. A comparative study of HER2/NEU oncogene in benign and malignant ovarian tumors. Int J Scientific study. 2014;2(4):50-4.

6. Claudine R, Isabelle M, Denis L, Alain P. The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer. Ovarian cancer- basic science perspective. Europe: IntTech; 2012: 67-84.

7. Gupta D, Christopher G. Role of CA125 in predicting ovarian cancer survival- a review of the epidemiological literature. J Ovarian Res. 2009;2:13.

8. Francisco C, Nadkarni N, Rebello M. Ovarian tumors in Goa: a clinicopathological study. J Obstet Gynecol India. 1993;43:408-12.

9. Rajan R. Analysis of ovarian pathologies in the modern perspective. Indian J Obstet Gynecol. 1994;44:764-70.

10. Sarkar R. ovarian neoplasms- A 14 years study. Obstet Gynecol J India. 1996; 46:156-9.

11. Sirriangkul S, Robbins KM, Silverberg SG. Ovarian mucinous tumors of low malignant potential. A clinicopathologic study of 54 tumors of intestinal and...
mullerian type. Int J Gynecol Pathol. 1995;14:198-208.
12. Fukazawa I, Inaba N, Ota Y, Sato N, Shivotake S, Iwasawa H, et al. Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease. Arch Gynecol Obstet. 1988;243(1):41-50.
13. Neunteufel W, Breitenecker G. Tissue expression of CA125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA. Gynecol Oncol. 1989;32(3):297-302.
14. Ajani MA, Salami A, Awolude OA, Oluwasola AO, Akang EE. The expression status of human epidermal growth factor receptor 2 in epithelial ovarian cancer in Ibadan, Nigeria. Southern African J Gynecol Oncol. 2016;8(1):9-13.
15. Marinas MC, Mogos G, Ciurea R, Mogos DG. EGFR, HER2/NEU and Ki67 immunoeexpression in serous ovarian tumors. Rom J Morphol Embryol. 2012;53(3):563-7.
16. Vrabie CD, Petrescu A, Waller M, Dina I. Clinical factors and biomarkers in ovarian tumors development. Rom J Morphol Embryol. 2008;49(3):327-38.
17. Mahdi MA. Overexpression of HER2/NEU in ovarian surface epithelial carcinoma in a sample of Iraqi patient at Al-Kindy teaching hospital. Al-Kindy Col Med J. 2013;9(1):126-32.

Cite this article as: Barbhuuya SB, Debnath A, Deka MK, Sheikh SA. Histopathological study of epithelial ovarian tumors with special reference to human epidermal growth factor receptor-2/NEU and CA-125 expression. Int J Res Med Sci 2021;9:1628-32.